Targeted intervention against PDGF isoforms offers a promising novel therapeutic approach to renal disease due to its central role in mesangial cell proliferation and fibrosis.
No takes yet. Share an insight, caveat, or question.
Does not yet support PDGF inhibition in practice; leaves open its viability as a target pending clinical trials.
Floege et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: